Nanobiosensors and Bioanalytical Applications Group (NanoB2A), Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, CIBER-BBN, Spain.
Nanobiosensors and Bioanalytical Applications Group (NanoB2A), Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, CIBER-BBN, Spain.
Biosens Bioelectron. 2023 Apr 15;226:115137. doi: 10.1016/j.bios.2023.115137. Epub 2023 Feb 8.
Monoclonal antibody (mAb) therapy is one of the most promising immunotherapies that have shown the potential to prevent or neutralize the effects of COVID-19 in patients at very early stages, with a few formulations recently approved by the European and American medicine agencies. However, a main bottleneck for their general implementation resides in the time-consuming, laborious, and highly-specialized techniques employed for the manufacturing and assessing of these therapies, excessively increasing their prices and delaying their administration to the patients. We propose a biomimetic nanoplasmonic biosensor as a novel analytical technique for the screening and evaluation of COVID-19 mAb therapies in a simpler, faster, and reliable manner. By creating an artificial cell membrane on the plasmonic sensor surface, our label-free sensing approach enables real-time monitoring of virus-cell interactions as well as direct analysis of antibody blocking effects in only 15 min assay time. We have achieved detection limits in the 10 TCID50/mL range for the study of SARS-CoV-2 viruses, which allows to perform neutralization assays by only employing a low-volume sample with common viral loads. We have demonstrated the accuracy of the biosensor for the evaluation of two different neutralizing antibodies targeting both Delta and Omicron variants of SARS-CoV-2, with half maximal inhibitory concentrations (IC) determined in the ng/mL range. Our user-friendly and reliable technology could be employed in biomedical and pharmaceutical laboratories to accelerate, cheapen, and simplify the development of effective immunotherapies for COVID-19 and other serious infectious diseases or cancer.
单克隆抗体 (mAb) 疗法是最有前途的免疫疗法之一，它具有在非常早期阶段预防或中和 COVID-19 对患者影响的潜力，最近已被欧美药品管理机构批准使用几种制剂。然而，其广泛实施的一个主要瓶颈在于制造和评估这些疗法所采用的耗时、费力且高度专业化的技术，这极大地增加了它们的价格，并延迟了它们对患者的使用。我们提出了一种仿生纳米等离子体生物传感器，作为一种新的分析技术，可以更简单、更快速和更可靠地筛选和评估 COVID-19 mAb 疗法。通过在等离子体传感器表面上创建人工细胞膜，我们的无标记传感方法能够实时监测病毒-细胞相互作用，并直接分析仅 15 分钟检测时间内的抗体阻断效果。我们已经实现了对 SARS-CoV-2 病毒的研究的 10 TCID50/mL 范围内的检测限，这使得仅使用具有常见病毒载量的小体积样本就可以进行中和测定。我们已经证明了该生物传感器用于评估两种针对 SARS-CoV-2 的 Delta 和 Omicron 变体的不同中和抗体的准确性，半最大抑制浓度 (IC) 在 ng/mL 范围内确定。我们用户友好且可靠的技术可用于生物医学和制药实验室，以加速、降低成本并简化 COVID-19 和其他严重传染病或癌症的有效免疫疗法的开发。
